<DOC>
	<DOCNO>NCT02364362</DOCNO>
	<brief_summary>Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 . Phase I study show toxicity manageable . This study assess safety maximum tolerate dose continuous daily treatment Famitinib plus docetaxel ( 60 mg/m^2 , every 3 week ) patient Advanced Non-squamous Non-Small Cell Lung Cancer ( NSCLC ) determine recommend dose Phase II trial .</brief_summary>
	<brief_title>A Study Famitinib Plus Docetaxel Patients With Advanced Non-squamous Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Age:1870 year ; 2 . ECOG PS ( Eastern Cooperative Oncology Group Performance Status ) 0 1 ; 3 . Life expectancy least 12 week ; 4 . Histologically cytologically confirm , locally advanced and/or metastatic NSCLC stage IIIB IV recurrent NSCLC ; 5 . Relapse failure one first line prior platinumbased chemotherapy ; EGFR mutation type previously treat platinumbased chemotherapy EGFR inhibitor ; 6 . At least one target tumour lesion irradiate within past 3 month accurately measure , accord RECIST 1.1 ; 7 . Participants adequate organ marrow function define : Hemoglobin ≥ 90g/L ( blood transfusion 2 week ) Absolute neutrophil count ( ANC ) ≥ 1.5×10^9/L Platelets ( PLT ) ≥ 100×10^9/L Bilirubin &lt; 1.25×ULN ( Upper Limit Of Normal ) ALT ＜ 2.5×ULN ; ALT ＜ 5×ULN ( If liver metastases ) AST ＜ 2.5×ULN ; AST ＜ 5×ULN ( If liver metastasis ) Serum creatinine ＜ 1.25×ULN , endogenous Cr clearance ＞ 45 ml/min ( CockcroftGault Formula ) Cholesterol ≤ 1.5×ULN triglyceride≤ 2.5×ULN Left ventricular ejection fraction ( LVEF ) : ≥ LLN ( Lower Limit Of Normal ) Color Doppler Ultrasonography 8 . Female : Child bear potential , negative urine serum pregnancy test result 7 day initiate famitinib.All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 8 week last dose test article . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 8 week last dose test article ; 9 . Patient give write informed consent . 1 . More one chemotherapy treatment regimen ( except , either neoadjuvant adjuvant neoadjuvant plus adjuvant ) advance and/or metastatic recurrent NSCLC ; 2 . Previous therapy VEGFR inhibitor ( include sunitinib , sorafenib , pazopanib , axitinib , bevacizumab ) docetaxel treatment NSCLC ; 3 . Radiographical evidence cavitary necrotic tumour ; 4 . Centrally locate tumours radiographical evidence ( CT MRI ) local invasion major blood vessel ; 5 . Preexisting ascites and/or clinically significant pleural effusion ; 6 . Pulmonary hemorrhage/ bleed event ≥ CTCAE gr . 2 initiate investigational drug ; 7 . History clinically significant haemoptysis within past 3 months（24h ＞half teaspoon） ; 8 . Current peripheral neuropathy great CTCAE grade 2 ; 9 . Other malignancy within past 3 year basal cell skin cancer , carcinoma situ cervix ; 10 . Active brain metastasis ( stable time ≤ 4 week , radiotherapy treatment , symptom , seizure treatment need ) leptomeningeal disease . ; 11 . Treatment investigational drug anticancer therapy , treatment another clinical trial within past 4 week start therapy concomitantly trial ; 12 . Persistence clinically relevant therapy relate toxicity previous chemotherapy and/or radiotherapy ; 13 . Treatment cytotoxic drug , radiotherapy ( except extremity brain ) , immunotherapy , monoclonal antibody , TKI inhibitor therapy within past 4 week , previous anticancer treatment interval ≤ 4 week . ; 14 . Patients hypertension use combination therapy ( systolic blood pressure＞140 mmHg , diastolic blood pressure＞90 mmHg ) . Patients unstable angina , myocardial ischemia myocardial infarction past 6 month , congestive heart failure＞NYHA II , arrhythmia ( include QTcF interval ≥ 450ms male 470ms female ) ; 15 . Urine protein ≥ + + confirm 24hour urinary protein＞1.0 g ; 16 . History major thrombotic clinically relevant major bleed event past 6 months，and know inherited predisposition bleed thrombosis ; 17 . PT APTT bias normal range≥50 % ; 18 . Application anticoagulant vitamin K antagonist warfarin , heparin analogue ; If prothrombin time international normalize ratio ( INR ) ≤ 1.5 , purpose prevention , use small dos warfarin ( 1mg orally , daily ) ， lowdose aspirin ( le 100mg daily ) allow ; 19 . Preexisting thyroid dysfunction , even use medical therapy , thyroid function maintain normal range ; 20 . Diabetes mellitus control hypoglycemic agent ; 21 . Active chronic hepatitis C and/or B infection liver dysfunction ; 22 . History immunodeficiency disease , concurrent acquire congenital immunodeficiency , history organ transplantation ; 23 . Serious infection require systemic antibiotic therapy ; 24 . Variety factor affect oral medication ( inability swallow , gastrointestinal resection , chronic diarrhea intestinal obstruction ) ; 25 . Significant weight loss ( ＞10 % ) within past 6 month ; 26 . Pregnancy , breast feeding child bear potential , positive urine serum pregnancy test result 7 day initiate famitinib ; 27 . Active alcohol drug abuse ; 28 . Any contraindication therapy docetaxel；History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 ( Tween 80 ) ；Hypersensitivity famitinib and/or excipients trial drugs；Hypersensitivity contrast medium ; 29 . Psychological , familial , sociological , geographical factor potentially hamper compliance study protocol followup schedule ; 30 . Patients unable comply protocol ; 31 . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>